Targeting inhibitory pathways in cancer immunotherapy.
The clinical success of adaptive transfer of in vitro expanded antigen-specific CD8(+) T cells isolated from patients' tumors has demonstrated that effector cells of the adaptive immune system can effectively eliminate even large tumor masses. Nevertheless, cancer vaccines that aim to expand such CD8(+) T cells in situ have had remarkably little success in spite of numerous attempts. Recent advances in basic immunology have revealed layers of complexity controlling activation and maintenance of adaptive immune responses that are tightly controlled by immunoinhibitory pathways to avoid horror autotoxicus. During tumor progression the activities of negative pathways increase and together with cancer immune evasion tactics presumably prevent induction of an efficacious immune response by cancer vaccines that solely provide more antigen to an already suppressed system. Cancer vaccines may thus need to readjust the imbalance of the cancer patients' immune system by inhibiting immunoinhibitors; such regimens have shown preclinical efficacy and are now entering clinical trials hopefully ending the Kafkaesque futility of cancer vaccines.
Lasaro
Marcio O
MO
The Wistar Institute, Philadelphia, PA 19104, USA. mlasaro@wistar.org
Ertl
Hildegund C J
HC
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D019139:Tumor Escape / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
J Exp Med. 2004 Dec 20;200(12):1613-22
15611289
J Clin Oncol. 2009 Sep 1;27(25):4035-7
19635998
J Exp Med. 1997 Jul 21;186(2):229-38
9221752
Immunol Today. 1997 Jun;18(6):292-9
9190116
Cancer Immunol Immunother. 2009 Mar;58(3):317-24
18704409
Mech Ageing Dev. 2009 Oct;130(10):709-12
19715717
Cell Immunol. 1983 Oct 15;81(2):298-305
6605806
Cytokine. 2000 Jun;12(6):547-54
10843728
Ageing Res Rev. 2004 Jan;3(1):15-29
15163101
Hum Immunol. 2008 Apr-May;69(4-5):241-9
18486758
J Leukoc Biol. 2010 Feb;87(2):223-35
20007250
Nat Immunol. 2008 Feb;9(2):176-85
18193050
Immunol Res. 2001;23(2-3):263-72
11444391
Nat Rev Microbiol. 2010 Jan;8(1):62-73
19966816
Lancet. 2007 Jun 2;369(9576):1861-1868
17544766
Nat Immunol. 2009 Jan;10(1):29-37
19043418
J Clin Oncol. 2005 Apr 1;23(10):2346-57
15800326
Immunol Rev. 2008 Aug;224:141-65
18759925
Clin Exp Immunol. 2005 Jun;140(3):540-6
15932517
Curr Opin Immunol. 2009 Aug;21(4):418-24
19570667
Immunol Lett. 2006 Jun 15;105(2):115-22
16580736
Curr Mol Med. 2009 Aug;9(6):725-31
19689299
N Engl J Med. 2009 Nov 5;361(19):1838-47
19890126
Semin Cancer Biol. 2002 Feb;12(1):43-50
11926411
World J Gastroenterol. 2009 Feb 7;15(5):513-20
19195051
J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55
19759364
Cancer Sci. 2009 Aug;100(8):1389-96
19459853
J Pathol. 2005 Jan;205(2):181-93
15641017
Nat Rev Immunol. 2007 May;7(5):391-401
17457345
J Immunol. 2010 May 15;184(10):5475-84
20410485
Ann N Y Acad Sci. 2009 Sep;1174:99-106
19769742
J Exp Med. 2008 Mar 17;205(3):711-23
18332179
Nat Rev Immunol. 2008 Jun;8(6):467-77
18500231
J Clin Invest. 2007 Nov;117(11):3383-92
17932562
J Immunol. 2007 Feb 15;178(4):1975-9
17277099
Cancer J. 2009 May-Jun;15(3):169-73
19556898
Nat Med. 2008 Feb;14(2):205-12
18193057
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5250-5
17875752
Curr Opin Immunol. 2007 Jun;19(3):309-14
17433872
Annu Rev Immunol. 2005;23:515-48
15771580
J Virol. 2003 Apr;77(8):4911-27
12663797
Int Immunol. 2007 Oct;19(10):1223-34
17898045
Hum Vaccin. 2009 Jan-Feb;5(1):6-14
18927514
Vaccine. 2000 Feb 25;18(16):1717-20
10689155
Cell. 1996 Nov 1;87(3):427-36
8898196
J Exp Med. 1996 Mar 1;183(3):959-70
8642299
Curr Opin Mol Ther. 2009 Feb;11(1):31-6
19169957
Cancer Res. 2010 Jan 1;70(1):109-18
20028856
Trends Mol Med. 2008 Dec;14(12):550-9
18986838
Exp Gerontol. 2009 Aug;44(8):517-22
19457448
J Immunol. 2008 May 15;180(10):6649-55
18453584
Front Biosci (Landmark Ed). 2009 Jan 01;14:1761-70
19273160
Semin Cancer Biol. 2007 Aug;17(4):317-29
17651986
Adv Immunol. 2006;90:297-339
16730267
Nat Immunol. 2005 Jan;6(1):90-8
15568026
Jpn J Clin Oncol. 2009 Feb;39(2):73-80
19015149
Curr Opin Immunol. 2004 Apr;16(2):143-50
15023405
Immunol Rev. 2009 May;229(1):145-51
19426220
Immunology. 2005 Jan;114(1):37-43
15606793
Mech Ageing Dev. 2009 Aug;130(8):509-17
19540259
J Clin Invest. 2007 May;117(5):1167-74
17476346
Adv Exp Med Biol. 1988;233:119-28
3146901
Immunol Res. 1999;20(2):101-8
10580635
Immunol Rev. 1997 Dec;160:63-77
9476666